Getty Images

GLP-1 Medication Use Is Linked with Lower Anxiety, Depression Rates

Epic Research published a study revealing a correlation between some GLP-1 drugs and lower diagnostic rates of anxiety and depression.

On Tuesday, February 6, 2024, Epic Research published the results of a dual-team Cosmos study, highlighting that taking certain glucagon-like peptide-1 (GLP-1) receptor agonists may reduce the chances of an anxiety or depression diagnosis.

These drugs are prescribed and FDA-approved to promote weight loss in overweight or obese patients and manage type 2 diabetes. The benefits associated with these medications have been vast, with multiple studies pointing out their impacts on cardiovascular and mental health. Despite some of the adverse side effects of GLP-1 drugs, research, such as the data presented in this Cosmos study, may reveal benefits that prompt further use or exploration of these drugs.

Semaglutide, liraglutide, and tirzepatide are FDA-approved for weight loss and management. The remainder of the GLP-1 drugs are only indicated for diabetes management. Although trizepatide was recently approved for weight loss in November 2023, the researchers did not account for trizepatide’s effects among non-diabetic patients.

Researchers evaluated the probability of a depression or anxiety diagnosis among patients using these drugs, stratifying the data based on the type of GLP-1 drug and participants’ diabetes status and comparing it to the baseline risk of depression and anxiety of the average person not taking GLP-1 medications.

Focusing on depression, the data showed that irrespective of diabetes status, liraglutide did not correlate with a significantly different depression risk. Comparatively, non-diabetic patients taking semaglutide were 37% less likely to be diagnosed with depression, while diabetic patients taking the drug were 45% less likely to be diagnosed with depression.

In diabetic patients, exenatide use correlated with an 11% reduction in depression diagnosis. Additionally, dulaglutide was linked to a 16% reduction in depression risk. The most significant change was in diabetic patients taking tirzepatide, as researchers linked this population with a 65% lower likelihood of anxiety.

Shifting the focus toward anxiety, in non-diabetic patients, liraglutide was not associated with a significant change in anxiety risk. However, diabetic patients taking liraglutide were 13% less likely to be diagnosed with anxiety.

Semaglutide use among non-diabetic patients was linked to a 31% lower probability of anxiety. More significantly, using this drug in diabetic patients correlated with a 44% lower chance of anxiety.

Once again, the most significant difference in anxiety rates was noted among diabetic patients taking tirzepatide, linking it to a 60% reduction in anxiety risk. Comparatively, exenatide use correlated with a 24% reduction in anxiety diagnosis, and dulaglutide was linked to a 22% reduction in anxiety risk.

The data from this study suggests that GLP-1 medications may have a positive effect on mental health; however, it does not identify a causational relationship between medication use and reduced rates of anxiety and depression. More insight is needed to evaluate the factors that contribute to these correlations.

Next Steps

Dig Deeper on Clinical trials and evidence

xtelligent Healthtech Analytics
xtelligent Healthcare Payers
xtelligent Health IT and EHR
xtelligent Healthtech Security
Close